Categories: Health

AVITA Medical to Host Investor Webinar Briefing

 | Source: AVITA Medical

VALENCIA, Calif., Aug. 10, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on August 14, 2025, at 9 AM Australian Eastern Daylight Time (August 13 at 4 PM U.S. Pacific Standard Time).

The webinar presentation will cover financial and business results from our recent second-quarter 2025 earnings webcast and will conclude with a Q&A session. Participants are invited to submit their questions via the registration page.

Register: https://us06web.zoom.us/webinar/register/WN_LkikThGHT0yE-xWNoH6bRw

A replay will be available on the AVITA Medical website, ir.avitamedical.com, following the presentation.

About AVITA Medical, Inc.

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burns and trauma wounds. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com
media@avitamedical.com

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

GlobeNews Wire

Recent Posts

Jaipur's Coolest Creative Festival Is Back: SHIFT 2025 Takes Over Birla Auditorium with Comedy, Crafts & Culture

SHIFT is Jaipur's ultimate, uber-cool New Gen Creative Festival. An arts and design event organised…

7 minutes ago

Anderson Diagnostics and MAHE Launch Groundbreaking Centre of Excellence in Reproductive Genomics

Anderson Diagnostics & Labs, Chennai, in a landmark partnership with Manipal Academy of Higher Education…

1 hour ago

Phemex Co-hosts LONGITUDE, Spotlighting the Next Era of Crypto Security at Its 6th Anniversary

APIA, Samoa, Dec. 12, 2025 /PRNewswire/ -- Phemex, a user-first crypto exchange, successfully co-hosted the…

2 hours ago

WSPN Achieves ISO/IEC 27001:2022 Certification, Reinforcing Its Commitment to World-Class Information Security

TORTOLA, British Virgin Islands, Dec. 12, 2025 /PRNewswire/ -- Worldwide Stablecoin Payment Network (WSPN), a leading…

2 hours ago

Accelerating Patient Recruitment and Research Excellence: TrialWire Supports Endpoints Clinical Trials Day NYC 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…

4 hours ago